Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4
- PMID: 2582709
- DOI: 10.1038/clpt.1989.180
Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4
Abstract
The metabolism of lidocaine to its major metabolite monoethylglycinexylidide (MEGX) was studied in human liver microsomes of 13 kidney transplant donors and of one patient with liver cirrhosis. Interindividual variation in metabolite formation was considerable. Biphasic kinetics indicated the involvement of at least two distinct enzymatic activities. With use of a series of antisera that recognize different human cytochrome P450 isozymes, we were able to identify an enzyme of the P450III gene family as one of two enzymes. By expressing human P450IIIA4 complementary deoxyribonucleic acid (cDNA) in HepG2 cells, we directly demonstrated lidocaine-deethylase activity for this P450 isozyme. These data suggest that P450IIIA4 is at least in part responsible for microsomal MEGX formation.
Similar articles
-
Metabolism of lidocaine by purified rat liver microsomal cytochrome P-450 isozymes.Biochem Pharmacol. 1989 Dec 15;38(24):4439-44. doi: 10.1016/0006-2952(89)90654-0. Biochem Pharmacol. 1989. PMID: 2604746
-
Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s.J Pharmacol Exp Ther. 1990 Dec;255(3):1385-91. J Pharmacol Exp Ther. 1990. PMID: 2262908
-
Metabolism of lidocaine by rat pulmonary cytochrome P450.Biochem Pharmacol. 1994 Mar 15;47(6):1061-6. doi: 10.1016/0006-2952(94)90418-9. Biochem Pharmacol. 1994. PMID: 8147905
-
The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.Toxicol Appl Pharmacol. 2004 Sep 15;199(3):193-209. doi: 10.1016/j.taap.2004.01.010. Toxicol Appl Pharmacol. 2004. PMID: 15364537 Review.
-
The clinical importance of conventional and quantitative liver function tests in liver transplantation.J Clin Pharm Ther. 2000 Dec;25(6):411-9. doi: 10.1046/j.1365-2710.2000.00308.x. J Clin Pharm Ther. 2000. PMID: 11123494 Review.
Cited by
-
The xenobiotic inhibitor profile of cytochrome P4502C8.Br J Clin Pharmacol. 2000 Dec;50(6):573-80. doi: 10.1046/j.1365-2125.2000.00316.x. Br J Clin Pharmacol. 2000. PMID: 11136296 Free PMC article.
-
Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.Br J Clin Pharmacol. 2003 Jan;55(1):86-93. doi: 10.1046/j.1365-2125.2003.01718.x. Br J Clin Pharmacol. 2003. PMID: 12534644 Free PMC article. Clinical Trial.
-
The Use of Intravenous Lidocaine in Perioperative Medicine: Anaesthetic, Analgesic and Immune-Modulatory Aspects.J Clin Med. 2022 Jun 20;11(12):3543. doi: 10.3390/jcm11123543. J Clin Med. 2022. PMID: 35743617 Free PMC article. Review.
-
Systemic Lidocaine Infusion for Acute Pain Management in a Surgical Intensive Care Unit: A Single-Arm Pilot Trial.J Clin Med. 2025 Jun 20;14(13):4390. doi: 10.3390/jcm14134390. J Clin Med. 2025. PMID: 40648763 Free PMC article.
-
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.Clin Pharmacokinet. 2005;44(3):279-304. doi: 10.2165/00003088-200544030-00005. Clin Pharmacokinet. 2005. PMID: 15762770 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources